A once-daily injectable used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It combines the long-acting basal insulin effect with the glucose-lowering and weight-modulating effects of a GLP-1 receptor agonist.

Indications:
- Improve glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient.
- Can be used in patients inadequately controlled on basal insulin or GLP-1 receptor agonists.

Main Active Ingredients:
- Insulin degludec 100 units/mL.
- Liraglutide 3.6 mg/mL.

Precautions:
- Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
- Do not use during episodes of hypoglycemia.
- Monitor for signs of thyroid C-cell tumors, pancreatitis, severe gastrointestinal reactions, or hypersensitivity.
- Avoid sharing injection pens.
- Monitor kidney function during episodes of dehydration.
- Adjust insulin regimen carefully to avoid hypo- or hyperglycemia.

Side Effects:
- Nasopharyngitis.
- Headache.
- Nausea.
- Diarrhea.
- Increased lipase.
- Upper respiratory tract infection.
- Hypoglycemia (common with insulin-containing products).
- Pancreatitis.

Drug-Drug Interactions:
- Anti-adrenergic drugs, such as metoprolol, atenolol, propranolol (beta-blockers), and clonidine, may reduce awareness of hypoglycemia.
- Concomitant oral medications, such as paracetamol (acetaminophen), ethinylestradiol/norgestimate (oral contraceptives), and amoxicillin, doxycycline (antibiotics), may have altered absorption due to delayed gastric emptying caused by liraglutide.